Glen Eagle Advisors, LLC Bio N Tech Se Transaction History
Glen Eagle Advisors, LLC
- $593 Billion
- Q3 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 100 shares of BNTX stock, worth $11,527. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$11,527
Previous $8.04 Million
47.8%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BNTX
# of Institutions
363Shares Held
38.1MCall Options Held
2.49MPut Options Held
2.26M-
Baillie Gifford & CO8.22MShares$948 Million0.74% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.41MShares$508 Million2.03% of portfolio
-
Primecap Management CO Pasadena, CA4.3MShares$495 Million0.39% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$218 Million0.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U01.81MShares$208 Million0.88% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $28B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...